Burmese pythons possess a remarkable ability to swallow and digest prey significantly larger than their heads. This ...

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

The specialty pharmacy industry is in a state of transformation, fueled by the rise of complex, innovative therapies and the ...

Integration boosts Grid AI’s deployment capacity as AI data-center power demand approaches 50 GW, growing by over 165% ...

Scientists found that DNA’s phosphate groups can direct chemical reactions to make the correct mirror-image form of drug ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Chemotherapy has long been a cornerstone of cancer treatment, but its effectiveness comes at a cost. The powerful drugs used ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Greetings, and welcome to the Codexis Third Quarter 2025 Earnings ...

Setanaxib is a novel enzyme-dependent hydrogen peroxide-depleting agent with anti-fibrotic and anti-inflammation properties. Setanaxib is in development for rare diseases such as Alport syndrome, ...

HYDERABAD: What was once a barren dumping yard filled with debris and sewage has been transformed into a thriving water body ...

Discover Codexis' Q3 2025 earnings highlights, strategic shift with Merck, and new leadership—positioning for growth in oligonucleotide manufacturing.

On World Retinol Day, experts debunk common myths surrounding this potent skincare ingredient. Dermatologists clarify that ...